(Q38041566)

27 August 2017

title

An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time (English)

1 reference

27 August 2017

0 references

2

1 reference

27 August 2017

Marta Romano

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

8 September 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1601-1610

1 reference

Origin, spread and demography of the Mycobacterium tuberculosis complex

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

21 January 2018

Immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Variation in protection by BCG: implications of and for heterologous immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Tuberculosis pathogenesis and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

The human model: a genetic dissection of immunity to infection in natural conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Retracted: Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Tuberculosis vaccines: a strategic blueprint for the next decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Vaccines against tuberculosis: where are we and where do we need to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

The success and failure of BCG - implications for a novel tuberculosis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Tuberculosis vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Novel human in vitro system for evaluating antimycobacterial vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

DNA vaccines: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Cell-mediated immune responses in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Should a new tuberculosis vaccine be administered intranasally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Aerosol vaccines for tuberculosis: a fine line between protection and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

A novel human IgA monoclonal antibody protects against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Simultaneous immunization against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

DNA vaccines against mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

Ten challenges for TB biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721768

10.1517/14712598.2012.721768

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference